Premium
F5‐03‐04: What does pharma want from academic drug discovery?
Author(s) -
Jones Declan
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.434
Subject(s) - order (exchange) , business , value (mathematics) , work (physics) , drug discovery , public relations , knowledge management , political science , engineering , computer science , biology , bioinformatics , finance , mechanical engineering , machine learning
evaluated CSF samples from subsets of two additional unique cohorts of HC and AD, including samples from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) and the Oxford Project to Investigate Memory and Ageing (OPTIMA) studies (J Alzheimers Dis. 44:525-539). Conclusions:These cohorts provide critical genotype, biochemical, imaging, cognitive and functional data with which to assess oligomers as potential surrogates of disease state. The ability of oligomers to differentiate between HC and AD, and the assessment of their performance in comparison with amyloid and tau, will be reported.